Kelly McDaniel1,2,3, Fanyin Meng1,2,3, Nan Wu2, Keisaku Sato2, Julie Venter2, Francesca Bernuzzi4, Pietro Invernizzi4, Tianhao Zhou2, Konstantina Kyritsi2, Ying Wan3,5, Qiaobing Huang5, Paolo Onori6, Heather Francis1,2,3, Eugenio Gaudio6, Shannon Glaser1,2, Gianfranco Alpini1,2. 1. Research, Central Texas Veterans Health Care System, Temple, TX. 2. Department of Medicine, Baylor Scott & White Health Digestive Disease Research Center, Texas A&M HSC and Baylor Scott & White Health, Temple, TX. 3. Research Institute, Baylor Scott & White Health, Temple, TX. 4. Liver Unit and Center for Autoimmune Liver Diseases, Humanitas Clinical and Research Center, Rozzano, Milan, Italy. 5. Department of Pathophysiology, Key Lab for Shock and Microcirculation Research of Guangdong Province, Southern Medical University, Guangzhou, China. 6. Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Sapienza, Rome, Italy.
Abstract
Biliary-committed progenitor cells (small mouse cholangiocytes; SMCCs) from small bile ducts are more resistant to hepatobiliary injury than large mouse cholangiocytes (LGCCs) from large bile ducts. The definitive endoderm marker, forkhead box A2 (FoxA2), is the key transcriptional factor that regulates cell differentiation and tissue regeneration. Our aim was to characterize the translational role of FoxA2 during cholestatic liver injury. Messenger RNA expression in SMCCs and LGCCs was assessed by polymerase chain reaction (PCR) array analysis. Liver tissues and hepatic stellate cells (HSCs) from primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) patients were tested by real-time PCR for methylation, senescence, and fibrosis markers. Bile duct ligation (BDL) and multidrug resistance protein 2 (MDR2) knockout mice (MDR2-/- ) were used as animal models of cholestatic liver injury with or without healthy transplanted large or small cholangiocytes. We demonstrated that FoxA2 was notably enhanced in murine liver progenitor cells and SMCCs and was silenced in human PSC and PBC liver tissues relative to respective controls that are correlated with the epigenetic methylation enzymes, DNA methyltransferase (DNMT) 1 and DNMT3B. Serum alanine aminotransferase and aspartate aminotransferase levels in nonobese diabetic/severe combined immunodeficiency mice engrafted with SMCCs post-BDL showed significant changes compared to vehicle-treated mice, along with improved liver fibrosis. Enhanced expression of FoxA2 was observed in BDL mouse liver after SMCC cell therapy. Furthermore, activation of fibrosis signaling pathways were observed in BDL/MDR2-/- mouse liver as well as in isolated HSCs by laser capture microdissection, and these signals were recovered along with reduced hepatic senescence and enhanced hepatic stellate cellular senescence after SMCC engraft. CONCLUSION: The definitive endoderm marker and the positive regulator of biliary development, FoxA2, mediates the therapeutic effect of biliary-committed progenitor cells during cholestatic liver injury. (Hepatology 2017;65:544-559).
Biliary-committed progenitor cells (small mouse cholangiocytes; SMCCs) from small bile ducts are more resistant to hepatobiliary injury than large mouse cholangiocytes (LGCCs) from large bile ducts. The definitive endoderm marker, forkhead box A2 (FoxA2), is the key transcriptional factor that regulates cell differentiation and tissue regeneration. Our aim was to characterize the translational role of FoxA2 during cholestatic liver injury. Messenger RNA expression in SMCCs and LGCCs was assessed by polymerase chain reaction (PCR) array analysis. Liver tissues and hepatic stellate cells (HSCs) from primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) patients were tested by real-time PCR for methylation, senescence, and fibrosis markers. Bile duct ligation (BDL) and multidrug resistance protein 2 (MDR2) knockout mice (MDR2-/- ) were used as animal models of cholestatic liver injury with or without healthy transplanted large or small cholangiocytes. We demonstrated that FoxA2 was notably enhanced in murine liver progenitor cells and SMCCs and was silenced in humanPSC and PBC liver tissues relative to respective controls that are correlated with the epigenetic methylation enzymes, DNA methyltransferase (DNMT) 1 and DNMT3B. Serum alanine aminotransferase and aspartate aminotransferase levels in nonobese diabetic/severe combined immunodeficiencymice engrafted with SMCCs post-BDL showed significant changes compared to vehicle-treated mice, along with improved liver fibrosis. Enhanced expression of FoxA2 was observed in BDL mouse liver after SMCC cell therapy. Furthermore, activation of fibrosis signaling pathways were observed in BDL/MDR2-/- mouse liver as well as in isolated HSCs by laser capture microdissection, and these signals were recovered along with reduced hepatic senescence and enhanced hepatic stellate cellular senescence after SMCC engraft. CONCLUSION: The definitive endoderm marker and the positive regulator of biliary development, FoxA2, mediates the therapeutic effect of biliary-committed progenitor cells during cholestatic liver injury. (Hepatology 2017;65:544-559).
Authors: S Glaser; M Wang; Y Ueno; J Venter; K Wang; H Chen; G Alpini; A Holterman Journal: Am J Physiol Gastrointest Liver Physiol Date: 2010-06-24 Impact factor: 4.052
Authors: G Alpini; C Ulrich; S Roberts; J O Phillips; Y Ueno; P V Podila; O Colegio; G D LeSage; L J Miller; N F LaRusso Journal: Am J Physiol Date: 1997-02
Authors: Rahul Kuver; Christopher E Savard; Sung Koo Lee; W Geoffrey Haigh; Sum P Lee Journal: Am J Physiol Gastrointest Liver Physiol Date: 2007-08-23 Impact factor: 4.052
Authors: Angela C Cheung; Maria J Lorenzo Pisarello; Nicholas F LaRusso Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-07-15 Impact factor: 5.187
Authors: Oihane Erice; Patricia Munoz-Garrido; Javier Vaquero; Maria J Perugorria; Maite G Fernandez-Barrena; Elena Saez; Alvaro Santos-Laso; Ander Arbelaiz; Raul Jimenez-Agüero; Joaquin Fernandez-Irigoyen; Enrique Santamaria; Verónica Torrano; Arkaitz Carracedo; Meenakshisundaram Ananthanarayanan; Marco Marzioni; Jesus Prieto; Ulrich Beuers; Ronald P Oude Elferink; Nicholas F LaRusso; Luis Bujanda; Jose J G Marin; Jesus M Banales Journal: Hepatology Date: 2018-02-21 Impact factor: 17.425